Current feasibility of endocrine therapy for breast cancer

Current feasibility of endocrine therapy for breast cancer

The paper considers the current feasibility of endocrine therapy for breast cancer (BC). It presents trials of the efficacy of fulvestrant in the treatment of patients with BC. Practically all clinical trials have demonstrated that the drug is well tolerated, without causing any significant systemic...

Full description

Bibliographic Details
Main Author:	I. V. Vysotskaya
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Opuholi Ženskoj Reproduktivnoj Sistemy
Subjects:	breast cancer endocrine therapy fulvestrant
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/142

Similar Items

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
by: Xu L, et al.
Published: (2018-11-01)

Brain metastases from breast cancer may respond to endocrine therapy: report of two cases
by: Wang Q, et al.
Published: (2019-02-01)

Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
by: L Yu Vladimirova
Published: (2016-12-01)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
by: Li Y, et al.
Published: (2020-06-01)

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
by: H. Hawle, et al.
Published: (2010-04-01)

Fulvestrant in the treatment of luminal metastatic breast cancer: the balance of effectiveness and safety
by: I. A. Koroleva, et al.
Published: (2020-07-01)

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
by: Javier A. Menendez, et al.
Published: (2020-10-01)

Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells
by: Liang Gao, et al.
Published: (2020-11-01)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
by: Mi Hwa Heo, et al.
Published: (2019-09-01)

Approaches to interpret the outcomes of a network meta-analysis on comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy
by: Jayaraj R, et al.
Published: (2019-04-01)

Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer
by: Muriel Lainé, et al.
Published: (2021-05-01)

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer
by: Carla L. Alves, et al.
Published: (2018-06-01)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
by: Rocca A, et al.
Published: (2018-08-01)

Novel strategies to improve the endocrine therapy of breast cancer
by: Aurelio Bartolome Castrellon
Published: (2017-05-01)

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
by: Alyssa Schlotman, et al.
Published: (2020-03-01)

Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement
by: Gao P, et al.
Published: (2018-05-01)

Metastatic breast cancer: Endocrine therapy landscape reshaped
by: Mohamad Adham Salkeni, et al.
Published: (2017-10-01)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
by: Giacomo Barchiesi, et al.
Published: (2020-05-01)

Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells
by: Pratima Basak, et al.
Published: (2018-11-01)

Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast Cancer
by: Toshihiko Takeiwa, et al.
Published: (2020-05-01)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
by: Florence Lerebours, et al.
Published: (2021-02-01)

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
by: Covadonga Martí, et al.
Published: (2021-05-01)

Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer
by: Senthil Rajappa, et al.
Published: (2018-01-01)

Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome
by: Indhuja Muthiah Vaikundaraja, et al.
Published: (2020-01-01)

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
by: Kamila Kaminska, et al.
Published: (2021-02-01)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
by: Leah K. Lambert, et al.
Published: (2018-07-01)

Fulvestrant in treatment for metastatic breast cancer
by: L. Yu. Vladimirova, et al.
Published: (2019-12-01)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
by: Junjie Li, et al.
Published: (2019-05-01)

A Time to Question: A Study of the Information Needs of Postmenopausal Breast Cancer Patients Regarding Endocrine Therapy
by: TeBrake, Melissa
Published: (2010)

Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC
by: Yu Cheng, et al.
Published: (2019-06-01)

Recent Progresses in Concurrent Chemotherapy and Endocrine Therapy for Breast Cancer
by: ZHANG Zechun, et al.
Published: (2018-02-01)

Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer
by: Leah K. Lambert, et al.
Published: (2021-04-01)

Use of Adjuvant Endocrine Therapy Among Post-Menopausal Breast Cancer Patients in Malaysia
by: Saiful Bahri A, et al.
Published: (2021-02-01)

Prevalence and determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore
by: Eskinder Eshetu Ali, et al.
Published: (2017-01-01)

Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review
by: Kirsti I. Toivonen, et al.
Published: (2021-12-01)

Association of Endocrine Therapy and Dementia in Women with Breast Cancer
by: Thompson MR, et al.
Published: (2021-04-01)

Does patient health literacy impact adherence to adjuvant endocrine therapy in breast cancer patients?
by: Keim-Malpass J, et al.
Published: (2018-12-01)

A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer
by: Adisorn Ratanaphan
Published: (2012-11-01)

Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
by: Jing Chen, et al.
Published: (2021-06-01)

Cannot write session to /tmp/vufind_sessions/sess_ggiaguj3itlbpi8btqrmb63nkg